15 completed. 15 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 15 |
| Phase 3 | 1 | Completed 1 |
Follow Relapsing Remitting Multiple Sclerosis: new trials by email Literature Review of Relapsing Remitting Multiple Sclerosis trials Research Report on Relapsing Remitting Multiple Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis PIPE-307 Dose A, PIPE-307 Dose B, Placebo - Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed | Janssen Research & Development, LLC | 182 | 2023-11-06 | 2026-09-25 |
| An Extension of the TG1101-RMS201 Trial Ublituximab - Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed | TG Therapeutics, Inc. | 48 | 2017-06-01 | 2022-12-21 |
| Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis IL2, Placebo - Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 30 | 2016-06-13 | 2020-11-09 |
| Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS) RHB-104 - Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed | RedHill Biopharma Limited | 18 | 2013-06-01 | 2016-07-28 |
| Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis Raltegravir - Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed | Queen Mary University of London | 23 | 2013-04-01 | 2017-05-30 |
| Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA) Boswellic acids (BOSWELAN) - Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed | Universitätsklinikum Hamburg-Eppendorf | 29 | 2011-09-01 | 2020-02-25 |
| A Phase IIa Study of NT-KO-003 for Multiple Sclerosis NT-KO-003 - Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed | Neurotec Pharma | 99 | 2011-06-01 | 2014-03-18 |
| Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis BAF312 - Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed | Novartis Pharmaceuticals | 185 | 2010-08-30 | 2018-03-27 |
| Treatment Interruption of Natalizumab natalizumab, interferon beta 1-a, methylprednisolone - Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed | Biogen | 175 | 2010-03-01 | 2013-09-19 |
| A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS) Estriol, Placebo, Copaxone - Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed | University of California, Los Angeles | 158 | 2007-03-01 | 2016-06-16 |
| A Study for Patients With Relapsing Remitting Multiple Sclerosis dirucotide, placebo - Relapsing Remitting Multiple Sclerosis | Phase 2 / Phase 3 | Completed | Eli Lilly and Company | 218 | 2006-11-01 | 2010-09-09 |
| BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis BHT-3009 0.5 mg, BHT-3009 1.5 mg, Placebo - Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed | Bayhill Therapeutics | 252 | 2006-02-01 | 2008-02-11 |
| A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod laquinimod 0.3, laquinimod 0.6, Placebo - Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 306 | 2005-03-01 | 2011-04-08 |
| Atorvastatin in Relapsing-Remitting Multiple Sclerosis interferon beta treatment to add-on atorvastatin treatment, untreated to atorvastatin treatment - Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed | Charite University, Berlin, Germany | 41 | 2003-10-01 | 2018-03-20 |
| A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis. glatiramer acetate 20 mg, glatiramer acetate 20 mg, with mitoxantrone - Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 40 | 2003-06-01 | 2011-04-14 |
Multiple Sclerosis, Relapsing-Remitting (15) · Multiple Sclerosis (4) · Autoimmune Diseases (1)
Autoimmune Diseases of the Nervous System (15) · Demyelinating Autoimmune Diseases, CNS (15) · Demyelinating Diseases (15) · Immune System Diseases (15) · Nervous System Diseases (15) · Autoimmune Diseases (14) · Multiple Sclerosis (11)
Glatiramer Acetate (3) · BHT 3009 (1) · Estriol (1) · Estrogens (1) · Interferon beta-1a (1) · Interleukin-2 (1) · MBP-8298 (1) · Methylprednisolone (1) · Mitoxantrone (1) · Natalizumab (1) · Raltegravir Potassium (1) · Sugars (1) · siponimod (1) · ublituximab (1)
Teva Branded Pharmaceutical Products R&D, Inc. (2) · Assistance Publique - Hôpitaux de Paris (1) · Bayhill Therapeutics (1) · Biogen (1) · Charite University, Berlin, Germany (1) · Eli Lilly and Company (1) · Janssen Research & Development, LLC (1) · Neurotec Pharma (1) · Novartis Pharmaceuticals (1) · Queen Mary University of London (1) · RedHill Biopharma Limited (1) · TG Therapeutics, Inc. (1) · University of California, Los Angeles (1) · Universitätsklinikum Hamburg-Eppendorf (1)
United States (5) · Germany (4) · Spain (3) · Canada (2) · Poland (2) · Russia (2) · Bulgaria (1) · Finland (1) · France (1) · Hungary (1) · Israel (1) · Italy (1) · Norway (1) · Serbia (1) · Slovakia (1)
Anne Cross, M.D. (1) · Anthony Reder, M.D. (1) · Barbara Giesser, M.D. (1) · Christoph Heesen, MD (1) · Corey Ford, M.D. (1) · David Klatzmann (1) · Dean Wingerchuk, M.D. (1) · Dina Jacobs, M.D. (1) · Elliot Frohman, M.D. (1) · Frank Valone, MD (1) · Frauke Zipp, MD (1) · Gareth Parry, M.D. (1) · Gavin Giovannoni (1) · Ira N Kalfus, MD (1)
PMID 18398457, PMID 18572078, PMID 26049148, PMID 26621682, PMID 27380540, PMID 30873106, PMID 37245191, PMID 38648580
2004 (1), 2009 (1), 2014 (1), R01NS051591 (1)